New article, but I think that I have already written about this...basically, it seems to delay castration resistance in prostate cancer.
"The analysis, which was performed to understand patient experiences post-progression, demonstrated that the median time to mCRPC was not reached (NR) in the triplet arm vs 19.1 months in the placebo group. Median OS was also NR vs 48.9 months in the triplet and placebo arms, respectively."
This article is a good reminder of what appears to be a broader principle in medicine: artful application of combination therapies can often produce more durable long-term responses (versus sequential therapies) although usually accompanied with more side effects.
This pattern has been seen in cancer treatment as well as other diseases, e.g., hypertension, diabetes, HIV.
With respect to cancer treatment, the idea is discussed in more depth here:
aacrjournals.org/cancerdisc...
Loved this phrase: "more durable long-term responses".
Have never seen this perspective expressed before. Almost an implication of chronic ...
That’s excellent, but i never want to be a placebo!
The longer I live with APCa, the more I see new de novo treatment combos for which that ship has sailed for me. Nice to know, but ...
Thanks for sharing max! "Not reached" (NR) is a wonderful metric. This news in different ways has been showing up in the last couple of months. More motivation to exercise!
When I want to cheer myself up….I read the updates to that trial!
great work Max, thanks from us all i reckon.
The article recently about some procedure where magnets are used for targetted was hopeful. I understand all these things take years but still nice to read.
Thinking About “Median Survival” in Clinical Trials. 
When Is ADT Right for Biochemically Recurrent Prostate Cancer? Study suggest early initiation may not "meaningfully" improve survival
Castration Resistance
Castration resistance
Radiotherapy in the Definitive Management of Oligometastatic Prostate Cancer
